P. Flandre, V. Calvez, G. Peytavin, V. Meiffredy, C. G. Delaugerre-410 et al., Mechanisms of virologic failure in previously untreated HIV-infected patients 412 from a trial of induction-maintenance therapy. Trilege (Agence Nationale de 413 Recherches sur le SIDA 072) Study Team), JAMA, vol.411, issue.2, pp.205-211, 2000.

D. Paterson, S. Swindells, J. Mohr, M. Brester, E. Vergis et al., Adherence to Protease Inhibitor Therapy and Outcomes in Patients with HIV Infection, Annals of Internal Medicine, vol.133, issue.1, pp.21-302109, 2000.
DOI : 10.7326/0003-4819-133-1-200007040-00004

A. Moss, Non-adherence to highly active antiretroviral therapy predicts 421 progression to AIDS, AIDS Bangsberg DR, vol.15, issue.5, pp.1181-1183, 2001.

J. Bamberger, M. Chesney, and A. Moss, Adherence to protease inhibitors, HIV- 424 1 viral load, and development of drug resistance in an indigent population, AIDS 425, vol.14, issue.6, pp.357-366, 2000.

C. Goujard, N. Bernard, N. Sohier, D. Peyramond, F. Lancon et al., Impact of a Patient Education Program on Adherence to HIV Medication, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.34, issue.2, pp.191-194, 2003.
DOI : 10.1097/00126334-200310010-00009

J. Parienti, D. Bangsberg, R. Verdon, and E. Gardner, Better Adherence with Once???Daily Antiretroviral Regimens: A Meta???Analysis, Clinical Infectious Diseases, vol.48, issue.4, pp.484-488, 2009.
DOI : 10.1086/596482

J. Bae, W. Guyer, K. Grimm, and F. Altice, Medication persistence in the treatment of HIV infection: a review of the literature and implications for future clinical care and research, AIDS, vol.25, issue.3, pp.279-290, 2011.
DOI : 10.1097/QAD.0b013e328340feb0

V. Journot and J. Moatti, The dynamic of adherence to highly active antiretroviral 436 therapy: results from the French National APROCO cohort, J Acquir Immune Defic 437 Syndr Glass TR, vol.28, issue.10, pp.232-239, 2001.

B. Hirschel, E. Bernasconi, M. Rickenbach, H. Gunthard, and H. Bucher, 440 Longitudinal analysis of patterns and predictors of changes in self-reported adherence 441 to antiretroviral therapy: Swiss HIV Cohort Study, J Acquir Immune Defic Syndr, vol.442, issue.443, pp.197-203, 2010.

D. Bangsberg, Not all missed doses are the same: sustained NNRTI treatment 445 interruptions predict HIV rebound at low-to-moderate adherence levels, PLoS One, vol.446, issue.3, pp.2783-447, 2008.

Y. Yazdanpanah, J. Dutheil, P. Perre, R. Verdon, and D. Bangsberg, Average 449 adherence to boosted protease inhibitor therapy, rather than the pattern of missed 450 doses, as a predictor of HIV RNA replication, Clin Infect Dis, vol.50, issue.451, pp.1192-1197, 2010.

J. Parienti, Patterns of adherence to raltegravir-based regimens and the risk of 453 virological failure among HIV-infected patients: the RALTECAPS cohort study, p.454, 2012.

S. Boyer, Time patterns of adherence and long-term virological response to non- 458 nucleoside reverse transcriptase inhibitor regimens in the Stratall ANRS 459 12110/ESTHER trial in Cameroon. Antivir Ther, p.15, 2013.

J. Milam, M. Cohen, G. Sharp, Y. Huang, and R. Greenblatt, Atazanavir 462 concentration in hair is the strongest predictor of outcomes on antiretroviral therapy, Clin Infect Dis, vol.463, issue.464, pp.1267-1275, 2011.

I. Wilson, E. Tchetgen, and D. Spiegelman, Patterns of adherence with 465 antiretroviral medications: an examination of between-medication differences, p.466, 2001.

J. Shuter, J. Sarlo, T. Kanmaz, R. Rode, and B. Zingman, HIV-infected 468 patients receiving lopinavir/ritonavir-based antiretroviral therapy achieve high rates of 469 virologic suppression despite adherence rates less than 95%, J Acquir Immune Defic, vol.470, issue.471, pp.4-8, 2007.

M. Chesney, E. Telzak, G. Friedland, and S. Mannheimer, Differential 473 adherence to combination antiretroviral therapy is associated with virological failure 474 with resistance, AIDS, vol.22, issue.475, pp.75-82, 2008.

D. Paterson, B. Potoski, B. Capitano, B. Vrijens, and J. Urquhart, Measurement of Adherence to Antiretroviral Medications, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.31, issue.21, pp.103-106616, 2002.
DOI : 10.1097/00126334-200212153-00003

B. Vrijens, E. Goetghebeur, E. De-klerk, R. Rode, S. Mayer et al., 485 Modelling the association between adherence and viral load in HIV-infected patients, Pharmacol Ther, vol.92, pp.575-83, 2005.

N. Ferguson, C. Donnelly, J. Hooper, A. Ghani, C. Fraser et al., Adherence to antiretroviral therapy and its impact on clinical outcome in HIV-infected patients, Journal of The Royal Society Interface, vol.2, issue.4, pp.349-363, 2005.
DOI : 10.1098/rsif.2005.0037

T. Maldonado, D. Duran, A. Kaplan, and N. Wenger, A comparison study of 493 multiple measures of adherence to HIV protease inhibitors, Ann Intern Med, vol.134, issue.495, pp.968-494, 2001.

K. Petersen, M. Riddle, L. Jones, K. Furtek, A. Christensen et al., Use of bilirubin as a marker of adherence to atazanavir-based antiretroviral therapy, AIDS, vol.19, issue.15, pp.1700-1702, 2005.
DOI : 10.1097/01.aids.0000186826.60983.85

M. Gisslen, A. Abelo, and M. Ashton, Bilirubin-a potential marker of drug exposure 500 in atazanavir-based antiretroviral therapy, AAPS J, vol.13, issue.501, pp.598-605, 2011.

V. Ormaasen, M. Vigan, A. Barrail-tran, M. Ashton, M. Gisslen et al., 503 External Validation of the Bilirubin-Atazanavir Nomogram for Assessment of 504, 2012.

J. Farley, S. Hines, A. Musk, S. Ferrus, and V. Tepper, Assessment of adherence to 506 antiviral therapy in HIV-infected children using the Medication Event Monitoring 507, 2003.

. System, provider assessment, caregiver self-report, and appointment 508 keeping, J Acquir Immune Defic Syndr, vol.33, issue.509, pp.211-218, 2010.

D. Bangsberg, Less Than 95% Adherence to Nonnucleoside Reverse???Transcriptase Inhibitor Therapy Can Lead to Viral Suppression, Clinical Infectious Diseases, vol.43, issue.7, pp.939-520, 2006.
DOI : 10.1086/507526

H. Liu, L. Miller, R. Hays, C. Golin, T. Wu et al., 526 Repeated measures longitudinal analyses of HIV virologic response as a function of 527 percent adherence, dose timing, genotypic sensitivity, and other factors, J Acquir Immune Defic Syndr Gill CJ, vol.528, issue.34, pp.315-322, 2006.

M. Desilva, Importance of dose timing to achieving undetectable viral loads. 531, AIDS Behav, vol.14, issue.532, pp.785-793, 2010.

L. Tiec, C. Barrail, A. Goujard, C. Taburet, and A. , Clinical Pharmacokinetics and Summary of Efficacy and Tolerability of Atazanavir, Clinical Pharmacokinetics, vol.63, issue.7, pp.1035-534, 2005.
DOI : 10.2165/00003088-200544100-00003

J. Shuter, J. Sarlo, R. Rode, and B. Zingman, Occurrence of Selective Ritonavir Nonadherence and Dose-Staggering in Recipients of Boosted HIV-1 Protease Inhibitor Therapy, HIV Clinical Trials, vol.2001134, issue.3, pp.135-142, 2009.
DOI : 10.7326/0003-4819-133-1-200007040-00004

M. Rosen, J. Simoni, I. Wilson, and R. Gross, Is Percentage Adherence Enough? 540 Correlation of the Various Adherence Metrics from the MACH14 Study, 7th 541 International Conference on HIV Treatment and Prevention Adherence, p.542

K. Nielsen-saines, D. Celentano, M. Essex, and T. Fleming, Prevention of HIV-1 553 infection with early antiretroviral therapy, N Engl J Med, vol.365, pp.493-505, 2011.

A. Geretti, C. Smith, A. Haberl, A. Garcia-diaz, G. Nebbia et al., Determinants of virological failure after successful viral load 556 suppression in first-line highly active antiretroviral therapy, Antivir Ther, vol.13, issue.557, pp.927-936, 2008.

R. Ellis, Validation of the CNS Penetration-Effectiveness rank for quantifying 560 antiretroviral penetration into the central nervous system, Arch Neurol, vol.65, issue.561, pp.65-70, 2008.

K. Mandaliya, J. Kiarie, W. Jaoko, J. Ndinya-achola, and J. Overbaugh, McClelland 563 RS Antiretroviral adherence and development of drug resistance are the 564 strongest predictors of genital HIV-1 shedding among women initiating treatment, J 565 Infect Dis, vol.202, issue.566, pp.1538-1542, 2010.

J. Nachega, Guidelines for Improving Entry Into and Retention in Care and 570, 2012.